PIRS: Pieris Pharmaceuticals Company Short-Term Debt

Symbol and logo of brand Pieris Pharmaceuticals, Inc. (PIRS)

Pieris Pharmaceuticals (PIRS) is currently undergoing a significant pipeline transformation following the termination of several pulmonary project agreements, making the price action chart a critical monitoring tool. The current metric stands at 0.00. The business focuses on developing inhaled therapies for cancer and respiratory diseases, mitigating risks through strategic partnerships. These developments leverage Anticalin protein engineering methods to achieve maximum treatment precision.

PIRS (Pieris Pharmaceuticals Inc) Company Short-Term Debts history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Pieris Pharma (PIRS)

- current quotes and average value forecast:
Price Chart Pieris Pharmaceuticals, Inc.|PIRS - Fair Value Consensus
- market capitalization information:
Market Value Pieris Pharmaceuticals, Inc.|PIRS - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Pieris Pharmaceuticals|PIRS - Book Capitalization|Market Cap to Net Assets Ratio pieris.com|PIRS - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Pieris Pharmaceuticals|PIRS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Pieris Pharmaceuticals|PIRS - Company Cumulative Indebtedness|Debts to Book Capitalization Pieris Pharmaceuticals, Inc.|PIRS - Company Long-Term Loans and Borrowings|Company Short-Term Debts Pieris Pharmaceuticals|Quick Liquidity pieris.com
- net income and valuation multiples indicators:
PIRS - Final Profit
Summary company analytics:Pieris Pharmaceuticals, Inc. (PIRS)
Mass-produced product of pieris.com

This indicator measures the aggregate volume of debt obligations maturing within one year, allowing for an assessment of current liquidity and business refinancing risks. By analyzing short-term balance sheet liabilities, investors determine the ability of Pieris Pharmaceuticals (PIRS) to sustain intensive R&D for antikalins and strategic partnerships without a critical working capital deficit during its active growth phase.

Competing companies

HLN - Company Short-Term Debt|Company Short-Term Loans and Borrowings KVUE (Kenvue Inc)|Verona Pharma Corp (VRNA) - Company Short-Term Debt|Company Current Liabilities Jyong Bio|LGND (Ligand Pharmaceuticals) - Company Short-Term Debts|Company Short-Term Debts amneal.com|Company Current Liabilities PRGO (Perrigo)|ALVO (Alvotech S.A.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Liquidia Technologies LQDA|Galapagos Corp (GLPG) - Short-Term Debt|ANIP: Company Current Liabilities|mannkindcorp.com - Amount of Current Liabilities|AMPH: Company Short-Term Debts|Pacira Pharmaceuticals - Company Short-Term Loans and Borrowings|SPRY (ARS Pharma) - Company Short-Term Debts|Short-Term Debt Theravance Corp TBPH|Company Short-Term Debt Aquestive Therapeutics (AQST)|SCPH (scpharmaceuticals.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Tectonic Therapeutic TECX|TNXP (Tonix Pharma) - Current Liabilities|SXT China - Company Short-Term Debts|Short-Term Debt Volume Eupraxia Pharmaceuticals EPRX|BHST: Company Short-Term Debts|Short-Term Debt invizyne.com (EXOZ)|Company Short-Term Debt Oramed|ENTX: Company Short-Term Loans and Borrowings|Company Short-Term Debts HYFT|Short-Term Debt Volume ABVC BioPharma, Inc|Company Short-Term Debt Cumberland Pharmaceuticals CPIX|Short-Term Debt Volume quantumbiopharma.com (QNTM)|FGEN: Company Current Liabilities|Company Short-Term Loans and Borrowings TELO (Telomir Pharmaceuticals Inc)|ranitherapeutics.com (RANI) - Company Short-Term Debt|Current Liabilities SNYR (Synergy CHC)|RLYB (Rallybio Corp) - Company Short-Term Debts|LEXX: Company Short-Term Loans and Borrowings|Company Short-Term Debts PULM|Company Short-Term Debts ftzy.com.cn (PTHL)|Company Short-Term Debt Aptorum Group APM|Company Short-Term Loans and Borrowings LYRA|IBO - Company Short-Term Debt|TNF Pharmaceuticals (TNFA) - Company Current Liabilities|YCBD: Company Short-Term Debts|PainReform Ltd (PRFX) - Company Short-Term Debts|CYTO (Altamira Therapeutics Ltd) - Company Short-Term Debts|Company Current Liabilities Lipella Pharma (LIPO)|Company Short-Term Debts OPTN|PROC - Short-Term Debt|Petros Pharmaceuticals, Inc. - Company Current Liabilities|Company Short-Term Debts Qilian International Holding Group QLI|SLRN: Company Current Liabilities|TFF Pharmaceuticals, Inc - Amount of Current Liabilities